Kivu Bioscience is focused on rapidly advancing next-generation transformative assets, particularly in the development of antibody-drug conjugates (ADCs) aimed at conquering cancer
Kivu Bioscience is focused on rapidly advancing next-generation transformative assets, particularly in the development of antibody-drug conjugates (ADCs) aimed at conquering cancer. The company utilizes advanced proprietary technologies to create highly stable ADCs with optimized linker and payload combinations, enhancing therapeutic efficacy while minimizing off-tumor toxicity.